Vanguard Group’s RenovoRx RNXT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$1.35M Hold
1,605,079
﹤0.01% 3697
2025
Q3
$2.04M Sell
1,605,079
-58,479
-4% -$69.5K ﹤0.01% 3578
2025
Q2
$2.2M Buy
1,663,558
+317,888
+24% +$362K ﹤0.01% 3505
2025
Q1
$1.33M Buy
1,345,670
+1,204,183
+851% +$1.4M ﹤0.01% 3625
2024
Q4
$183K Buy
141,487
+84,750
+149% +$96.5K ﹤0.01% 4114
2024
Q3
$60.1K Hold
56,737
﹤0.01% 4236
2024
Q2
$64.1K Hold
56,737
﹤0.01% 4271
2024
Q1
$76K Buy
56,737
+159
+0.3% +$230 ﹤0.01% 4265
2023
Q4
$130K Sell
56,578
-18,155
-24% -$17.3K ﹤0.01% 4275
2023
Q3
$99.4K Buy
74,733
+19,250
+35% +$34.6K ﹤0.01% 4351
2023
Q2
$125K Buy
55,483
+10,290
+23% +$25K ﹤0.01% 4370
2023
Q1
$157K Buy
45,193
+34,252
+313% +$121K ﹤0.01% 4352
2022
Q4
$25.7K Buy
10,941
+126
+1% +$241 ﹤0.01% 4483
2022
Q3
$22K Hold
10,815
﹤0.01% 4588
2022
Q2
$21K Hold
10,815
﹤0.01% 4610
2022
Q1
$32K Buy
+10,815
New +$37.9K ﹤0.01% 4621

Other funds holding RNXT

Vanguard Group's RNXT Position: Q4 2025 in Review

Vanguard Group held its RenovoRx (RNXT) position steady in Q4 2025 at 1,605,079 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #3697.

Vanguard Group first reported a position in RNXT in Q1 2022 and has held it in 16 quarters since. The position peaked at $2.2M in Q2 2025. 33 funds tracked by Wall St. Rank hold RNXT as of Q4 2025.

  • Vanguard Group held 1,605,079 shares of RenovoRx worth $1.35M as of Q4 2025.
  • Vanguard Group left its RenovoRx share count unchanged in Q4 2025.
  • RenovoRx made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3697 holding.
  • Vanguard Group first reported a position in RenovoRx in Q1 2022 and has held it in 16 quarters since.
  • Vanguard Group's RenovoRx position peaked at $2.2M in Q2 2025.
  • 33 funds tracked by Wall St. Rank held RenovoRx as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.